PLAY PODCASTS
Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios
Episode 334

Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios

Listen to expert faculty share their approach to optimizing antimicrobial therapy in complex clinical cases caused by carbapenem-resistant Acinetobacter baumannii.

Decera Clinical Education Infectious Disease Podcast · Trevor Van Schooneveld MD FSHEA FACP, Emily Heil PharmD MS BCIDP AAHIVP, Laila Woc Colburn MD

November 15, 202328m 44s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: 

  • Mechanisms for β-lactam resistance
  • Additional resistance mechanisms and virulence factors
  • 2023 IDSA guidance recommendations for moderate to severe CRAB infections
  • The latest clinical data by antimicrobial therapy/regimen:
  • Sulbactam
  • Meropenem and colistin
  • Carbapenem, sulbactam, and polymyxin B
  • Tetracyclines
  • Cefiderocol
  • Sulbactam/durlobactam and carbapenems
     

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP 
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland 
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine 
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: 
https://bit.ly/476v2wI

Link to full program: 
https://bit.ly/40Mmicz


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

sulbactamsevere infectiongeographicvirulence factorsapeks-npesblbiofilm formationidsa guidanceaminoglycosidestetracyclinesbeta-lactamscolistincrabcredible-crcombination therapysulbactam/durlobactamminocyclineovercomesoft tissuepbpsbeta-lactamasesmechanisms of resistanceoxatopoisomerase modificationsauc:mic ratiotriple therapypolymyxin bmiccarbapenemasescefiderocolpk/pdattackhigh dose ampicillin/sulbactamporin expressionaidaosteoarticulartigecyclinemeropenemfluoroquinolonesampcmblmoderate infectiont>mic